SRR8942952
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.540
- E2F_TARGETS+0.500
- TGF_BETA_SIGNALING+0.450
- CHOLESTEROL_HOMEOSTASIS+0.430
- MYC_TARGETS_V2+0.410
- MITOTIC_SPINDLE+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.380
- MYC_TARGETS_V1+0.370
- PI3K_AKT_MTOR_SIGNALING+0.350
- MTORC1_SIGNALING+0.330
Top 10 suppressed
- COAGULATION-0.230
- PANCREAS_BETA_CELLS-0.180
- KRAS_SIGNALING_DN-0.150
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
- FATTY_ACID_METABOLISM-0.130
- BILE_ACID_METABOLISM-0.120
- HEDGEHOG_SIGNALING-0.090
- KRAS_SIGNALING_UP-0.080
- XENOBIOTIC_METABOLISM-0.080
- MYOGENESIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.846 |
| 2 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.846 |
| 3 | SRR934851 | — | — | 0.844 |
| 4 | R315 | — | — | 0.842 |
| 5 | TCGA-FD-A3N5-01A-11R-A21D-07 | — | — | 0.841 |
| 6 | TCGA-78-7146-01A-11R-2039-07 | — | cohortA1 | 0.841 |
| 7 | SRR650195 | — | — | 0.838 |
| 8 | SRR650183 | — | — | 0.825 |
| 9 | TCGA-FD-A3N6-01A-11R-A21D-07 | — | — | 0.822 |
| 10 | MDT-AP-3375 | Med | Medulloblastoma | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |